1
|
Singh AD, Bergman L and Seregard S: Uveal
melanoma: Epidemiologic aspects. Ophthalmol Clin North Am.
18:75–84. viii2005. View Article : Google Scholar : PubMed/NCBI
|
2
|
Singh AD, Turell ME and Topham AK: Uveal
melanoma: Trends in incidence, treatment, and survival.
Ophthalmology. 118:1881–1885. 2011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Bedikian AY, Johnson MM, Warneke CL,
Papadopoulos NE, Kim KB, Hwu WJ, McIntyre S, Rohlfs M, Homsi J and
Hwu P: Does complete response to systemic therapy in patients with
stage IV melanoma translate into long-term survival? Melanoma Res.
21:84–90. 2011. View Article : Google Scholar
|
4
|
Damato B and Heimann H: Personalized
treatment of uveal melanoma. Eye (Lond). 27:172–179. 2013.
View Article : Google Scholar
|
5
|
Li B, Li YY, Tsao SW and Cheung AL:
Targeting NF-κB signaling pathway suppresses tumor growth,
angiogenesis, and metastasis of human esophageal cancer. Mol Cancer
Ther. 8:2635–2644. 2009. View Article : Google Scholar : PubMed/NCBI
|
6
|
Sakamoto K and Maeda S: Targeting NF-κB
for colorectal cancer. Expert Opin Ther Targets. 14:593–601. 2010.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Luedde T and Schwabe RF: NF-κB in the
liver - linking injury, fibrosis and hepatocellular carcinoma. Nat
Rev Gastroenterol Hepatol. 8:108–118. 2011. View Article : Google Scholar : PubMed/NCBI
|
8
|
Nogueira L, Ruiz-Ontañon P,
Vazquez-Barquero A, Moris F and Fernandez-Luna JL: The NF-κB
pathway: A therapeutic target in glioblastoma. Oncotarget.
2:646–653. 2011. View Article : Google Scholar : PubMed/NCBI
|
9
|
Lu Z, Jin Y, Chen C, Li J, Cao Q and Pan
J: Pristimerin induces apoptosis in imatinib-resistant chronic
myelogenous leukemia cells harboring T315I mutation by blocking
NF-κB signaling and depleting Bcr-Abl. Mol Cancer. 9:1122010.
View Article : Google Scholar
|
10
|
Rinkenbaugh AL and Baldwin AS: The NF-κB
pathway and cancer stem cells. Cells. 5:52016. View Article : Google Scholar
|
11
|
Lee CH, Jeon YT, Kim SH and Song YS: NF-κB
as a potential molecular target for cancer therapy. Biofactors.
29:19–35. 2007. View Article : Google Scholar
|
12
|
Dror R, Lederman M, Umezawa K, Barak V,
Pe'er J and Chowers I: Characterizing the involvement of the
nuclear factor-κB (NF κB) transcription factor in uveal melanoma.
Invest Ophthalmol Vis Sci. 51:1811–1816. 2010. View Article : Google Scholar
|
13
|
Dirsch VM, Kiemer AK, Wagner H and Vollmar
AM: The triterpenoid quinonemethide pristimerin inhibits induction
of inducible nitric oxide synthase in murine macrophages. Eur J
Pharmacol. 336:211–217. 1997. View Article : Google Scholar
|
14
|
Yousef BA, Hassan HM, Zhang LY and Jiang
ZZ: Anticancer potential and molecular targets of pristimerin: A
mini-review. Curr Cancer Drug Targets. 17:100–108. 2017. View Article : Google Scholar
|
15
|
Lee SO, Kim JS, Lee MS and Lee HJ:
Anti-cancer effect of pristimerin by inhibition of HIF-1α involves
the SPHK-1 pathway in hypoxic prostate cancer cells. BMC Cancer.
16:7012016. View Article : Google Scholar
|
16
|
Xie G, Yu X, Liang H, Chen J, Tang X, Wu S
and Liao C: Pristimerin overcomes adriamycin resistance in breast
cancer cells through suppressing Akt signaling. Oncol Lett.
11:3111–3116. 2016.PubMed/NCBI
|
17
|
Yousef BA, Hassan HM, Guerram M, Hamdi AM,
Wang B, Zhang LY and Jiang ZZ: Pristimerin inhibits proliferation,
migration and invasion, and induces apoptosis in HCT-116 colorectal
cancer cells. Biomed Pharmacother. 79:112–119. 2016. View Article : Google Scholar : PubMed/NCBI
|
18
|
Zhao H, Wang C, Lu B, Zhou Z, Jin Y, Wang
Z, Zheng L, Liu K, Luo T, Zhu D, et al: Pristimerin triggers
AIF-dependent programmed necrosis in glioma cells via activation of
JNK. Cancer Lett. 374:136–148. 2016. View Article : Google Scholar : PubMed/NCBI
|
19
|
Deng Q, Bai S, Gao W and Tong L:
Pristimerin inhibits angiogenesis in adjuvant-induced arthritic
rats by suppressing VEGFR2 signaling pathways. Int Immunopharmacol.
29:302–313. 2015. View Article : Google Scholar : PubMed/NCBI
|
20
|
Huang S, He P, Peng X, Li J, Xu D and Tang
Y: Pristimerin inhibits prostate cancer bone metastasis by
targeting PC-3 stem cell characteristics and VEGF-induced
vasculogenesis of BM-EPCs. Cell Physiol Biochem. 37:253–268. 2015.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Yousef BA, Guerram M, Hassan HM, Hamdi AM,
Zhang LY and Jiang ZZ: Pristimerin demonstrates anticancer
potential in colorectal cancer cells by inducing G1 phase arrest
and apoptosis and suppressing various pro-survival signaling
proteins. Oncol Rep. 35:1091–1100. 2016.PubMed/NCBI
|
22
|
Zuo J, Guo Y, Peng X, Tang Y, Zhang X, He
P, Li S, Wa Q, Li J, Huang S, et al: Inhibitory action of
pristimerin on hypoxia-mediated metastasis involves stem cell
characteristics and EMT in PC-3 prostate cancer cells. Oncol Rep.
33:1388–1394. 2015.PubMed/NCBI
|
23
|
Ma YW, Liu YZ and Pan JX: Verteporfin
induces apoptosis and eliminates cancer stem-like cells in uveal
melanoma in the absence of light activation. Am J Cancer Res.
6:2816–2830. 2016.
|
24
|
Jin B, Ding K and Pan J: Ponatinib induces
apoptosis in imatinib-resistant human mast cells by
dephosphorylating mutant D816V KIT and silencing β-catenin
signaling. Mol Cancer Ther. 13:1217–1230. 2014. View Article : Google Scholar : PubMed/NCBI
|
25
|
Jin Y, Lu Z, Ding K, Li J, Du X, Chen C,
Sun X, Wu Y, Zhou J and Pan J: Antineoplastic mechanisms of
niclosamide in acute myelogenous leukemia stem cells: Inactivation
of the NF-κB pathway and generation of reactive oxygen species.
Cancer Res. 70:2516–2527. 2010. View Article : Google Scholar : PubMed/NCBI
|
26
|
Jin Y, Zhou J, Xu F, Jin B, Cui L, Wang Y,
Du X, Li J, Li P, Ren R, et al: Targeting methyltransferase PRMT5
eliminates leukemia stem cells in chronic myelogenous leukemia. J
Clin Invest. 126:3961–3980. 2016. View Article : Google Scholar : PubMed/NCBI
|
27
|
Pan J, Quintás-Cardama A, Kantarjian HM,
Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ and
Verstovsek S: EXEL-0862, a novel tyrosine kinase inhibitor, induces
apoptosis in vitro and ex vivo in human mast cells expressing the
KIT D816V mutation. Blood. 109:315–322. 2007. View Article : Google Scholar
|
28
|
Jin B, Wang C, Li J, Du X, Ding K and Pan
J: Anthelmintic niclosamide disrupts the interplay of p65 and
FOXM1/β-catenin and eradicates leukemia stem cells in chronic
myelogenous leukemia. Clin Cancer Res. 23:789–803. 2017. View Article : Google Scholar
|
29
|
Dai W, Zhou J, Jin B and Pan J: Class
III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses
migration and eliminates cancer stem cells in uveal melanoma. Sci
Rep. 6:226222016. View Article : Google Scholar : PubMed/NCBI
|
30
|
Morrison DJ, Hogan LE, Condos G, Bhatla T,
Germino N, Moskowitz NP, Lee L, Bhojwani D, Horton TM,
Belitskaya-Levy I, et al: Endogenous knockdown of survivin improves
chemotherapeutic response in ALL models. Leukemia. 26:271–279.
2012. View Article : Google Scholar
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
32
|
Yarrow JC, Perlman ZE, Westwood NJ and
Mitchison TJ: A high-throughput cell migration assay using scratch
wound healing, a comparison of image-based readout methods. BMC
Biotechnol. 4:212004. View Article : Google Scholar : PubMed/NCBI
|
33
|
Dinicola S, Pasqualato A, Cucina A,
Coluccia P, Ferranti F, Canipari R, Catizone A, Proietti S,
D'Anselmi F, Ricci G, et al: Grape seed extract suppresses
MDA-MB231 breast cancer cell migration and invasion. Eur J Nutr.
53:421–431. 2014. View Article : Google Scholar
|
34
|
Toth M and Fridman R: Assessment of
gelatinases (MMP-2 and MMP-9 by gelatin zymography. Methods Mol
Med. 57:163–174. 2001.PubMed/NCBI
|
35
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar
|
36
|
Nonaka M, Yawata T, Takemura M, Higashi Y,
Nakai E, Shimizu K and Ueba T: Elevated cell invasion in a tumor
sphere culture of RSV-M mouse glioma cells. Neurol Med Chir
(Tokyo). 55:60–70. 2015. View Article : Google Scholar
|
37
|
Chen LF and Greene WC: Shaping the nuclear
action of NF-κB. Nat Rev Mol Cell Biol. 5:392–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
38
|
Liu YB, Gao X, Deeb D, Brigolin C, Zhang
Y, Shaw J, Pindolia K and Gautam SC: Ubiquitin-proteasomal
degradation of antiapop-totic survivin facilitates induction of
apoptosis in prostate cancer cells by pristimerin. Int J Oncol.
45:1735–1741. 2014.PubMed/NCBI
|
39
|
Huang Q, Lan F, Wang X, Yu Y, Ouyang X,
Zheng F, Han J, Lin Y, Xie Y, Xie F, et al: IL-1β-induced
activation of p38 promotes metastasis in gastric adenocarcinoma via
upregulation of AP-1/c-fos, MMP2 and MMP9. Mol Cancer. 13:182014.
View Article : Google Scholar
|
40
|
Clarke MF, Dick JE, Dirks PB, Eaves CJ,
Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer
stem cells-perspectives on current status and future directions:
AACR Workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006.
View Article : Google Scholar : PubMed/NCBI
|
41
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
42
|
Bronkhorst IH and Jager MJ: Inflammation
in uveal melanoma. Eye (Lond). 27:217–223. 2013. View Article : Google Scholar
|
43
|
Nagarkatti-Gude N, Bronkhorst IH, van
Duinen SG, Luyten GP and Jager MJ: Cytokines and chemokines in the
vitreous fluid of eyes with uveal melanoma. Invest Ophthalmol Vis
Sci. 53:6748–6755. 2012. View Article : Google Scholar : PubMed/NCBI
|
44
|
Storci G, Sansone P, Mari S, D'Uva G,
Tavolari S, Guarnieri T, Taffurelli M, Ceccarelli C, Santini D,
Chieco P, et al: TNFalpha up-regulates SLUG via the
NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a
stem cell-like phenotype. J Cell Physiol. 225:682–691. 2010.
View Article : Google Scholar : PubMed/NCBI
|